Fiber-type caffeine sensitivities in skinned muscle fibers from humans susceptible to malignant hyperthermia.
BACKGROUND
The response to contracture tests may depend upon the relative proportion of muscle fiber types within the muscle specimen. To determine whether a difference in fiber-type caffeine sensitivities exists between malignant hyperthermia susceptible (MHS) and malignant hyperthermia-nonsusceptible (MHN) skeletal muscle, we compared the fiber-type caffeine sensitivities in chemically skinned muscle fibers dissected from vastus lateralis muscle from 15 MHS and 16 MHN patients.


METHODS
Muscle fiber type was determined in each fiber by the difference in strontium-induced tension measurements and in 36 fibers, after contracture testing, by ATPase enzyme histochemistry. Caffeine sensitivity was defined as the threshold concentration inducing more than 10% of the maximal tension obtained with a calcium 1.6 x 10(-2) mM solution.


RESULTS
Significant difference in the mean (+/- SD) caffeine sensitivity was found between type I MHS fibers (2.63 +/- 0.85 mM) versus type II MHS fibers (3.47 +/- 1.2 mM) and between type I MHN fibers (5.89 +/- 1.8 mM) versus type II MHN fibers (10.46 +/- 2.6 mM). The mean (+/- SD) caffeine sensitivities for a given muscle fiber type (I or II) were different between groups of MHS and MHN patients. Both type I and II MHS fibers had significantly lower caffeine sensitivities, and this increase in caffeine sensitivity was significantly smaller in type I than in type II fiber.


CONCLUSIONS
The current study indicates that a truly MHS patient cannot have a false-negative result solely related to abnormal type II fibers contained in a given muscle strip. Although the occurrence of a very high proportion of type I fibers in MHN human muscle could result in a false-positive contracture outcome, such an occurrence is expected to be rare.
Adnet
P J
PJ
Département d'Anesthésie-Réanimation Chirurgicale I, Hôpital B, Centre Hospitalier Régional Universitaire, Lille, France.
Bromberg
N L
NL
Haudecoeur
G
G
Krivosic
I
I
Adamantidis
M M
MM
Reyford
H
H
Bello
N
N
Krivosic Horber
R M
RM
D002110:Caffeine / Q000494:pharmacology*; D004198:Disease Susceptibility / Q000503:physiopathology; D006801:Humans; D066298:In Vitro Techniques; D008305:Malignant Hyperthermia / Q000503:physiopathology*; D009132:Muscles / Q000187:drug effects* / Q000502:physiology
D002110:Caffeine